Stemedica Announces the Appointment of Dr. Cesar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America
Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s allogeneic adult stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.
San Diego, CA, July 02, 2010 --(PR.com)-- Stemedica Cell Technologies, Inc., a leader in allogeneic adult stem cell manufacturing, research and development announced today the appointment of Cesar Amescua, MD as Medical and Regulatory Affairs Director for Latin America. Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.
Dr Amescua is a member of the senior medical leadership at Groupo Angeles, one of the largest health care providers in all of Latin America. He is also President of the Mexican Association for the Study and Treatment of Pain. “I am excited and proud to be working with Stemedica. The company is a leader in the stem cell manufacturing field, and is bringing innovative technology to countries around the world. Latin America holds great promise for Stemedica’s products and services as Latin America seeks to address the epidemic of degenerative diseases and conditions that are bankrupting health care systems around the world.”
Dr. Lev Verkh, Stemedica’s Chief Regulatory and Clinical Development Officer, commented, “We’re pleased and delighted to have Dr Amescua joining our team at Stemedica. His medical leadership and his regulatory expertise will be critical in establishing clinical trials throughout Latin America using Stemedica stem cell products.”
“With the rapid advancement of the clinical application and development of adult stem cell therapy around the world, the addition of Dr. Amescua’s medical leadership and regulatory expertise is critical in establishing extensive clinical trials for our products,” said Dr. Nikolai Tankovich, Stemedica’s President and Chief Medical Officer.
About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for its clinical trials for ischemic stroke. Stemedica is currently developing regulatory pathways for a number of medical indications using adult allogeneic stem cells. The Company is headquartered in San Diego, California.
For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan@stemedica.com.
###
Dr Amescua is a member of the senior medical leadership at Groupo Angeles, one of the largest health care providers in all of Latin America. He is also President of the Mexican Association for the Study and Treatment of Pain. “I am excited and proud to be working with Stemedica. The company is a leader in the stem cell manufacturing field, and is bringing innovative technology to countries around the world. Latin America holds great promise for Stemedica’s products and services as Latin America seeks to address the epidemic of degenerative diseases and conditions that are bankrupting health care systems around the world.”
Dr. Lev Verkh, Stemedica’s Chief Regulatory and Clinical Development Officer, commented, “We’re pleased and delighted to have Dr Amescua joining our team at Stemedica. His medical leadership and his regulatory expertise will be critical in establishing clinical trials throughout Latin America using Stemedica stem cell products.”
“With the rapid advancement of the clinical application and development of adult stem cell therapy around the world, the addition of Dr. Amescua’s medical leadership and regulatory expertise is critical in establishing extensive clinical trials for our products,” said Dr. Nikolai Tankovich, Stemedica’s President and Chief Medical Officer.
About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for its clinical trials for ischemic stroke. Stemedica is currently developing regulatory pathways for a number of medical indications using adult allogeneic stem cells. The Company is headquartered in San Diego, California.
For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan@stemedica.com.
###
Contact
Stemedica Cell Technologies, Inc.
Dave McGuigan
858-658-0910
http://www.stemedica.com/
Street - 5375 Mira Sorrento Place, Suite 120
City - San Diego
State - CA
Zip - 92121
Country - United States
Dave McGuigan
858-658-0910
http://www.stemedica.com/
Street - 5375 Mira Sorrento Place, Suite 120
City - San Diego
State - CA
Zip - 92121
Country - United States
Contact
Categories